Suppressive Activity of Mefloquine in Sporozoite-Induced Human Malaria1

AUTOR(ES)

Clyde, David F.

RESUMO

Mefloquine hydrochloride [WR 142,490; α-(2-piperidyl)-2,8-bis(trifluoromethyl)-4-quinolinemethanol hydrochloride] was tested for suppressive effect on sporozoite-induced malaria in nonimmune volunteers living in an area where malaria is not naturally transmitted. Single doses of 250 mg were given at weekly intervals, 500 mg at intervals of 2 weeks and 1,000 mg at intervals of 4 weeks, to men bitten by 10 to 15 mosquitoes heavily infected with a chloroquine- and pyrimethamine-resistant strain of Plasmodium falciparum. None of the individuals so treated developed infections during the period of drug delivery or during the follow-up period of 60 days. Doses of 250 or 500 mg produced no adverse reactions; mild epigastric discomfort occurred in all three men given 1,000 mg. Sporozoite-induced P. vivax infections were suppressed by single doses of 250 mg of mefloquine given at weekly intervals, but malaria developed after completion of the course. At treatment intervals longer than 1 week, vivax malaria was not suppressed.

Documentos Relacionados

• A STUDY OF THE PROPHYLACTIC EFFECTIVENESS OF SEVERAL 8-AMINOQUINOLINES IN SPOROZOITE-INDUCED VIVAX MALARIA (CHESŚON STRAIN) 1
• THE THERAPEUTIC EFFECTIVENESS OF LARGE DOSES OF PALUDRINE IN ACUTE ATTACKS OF SPOROZOITE-INDUCED VIV AX MALARIA (CHESSON STRAIN) 1
• THE USE OF SN-10,275 IN THE PROPHYLAXIS AND TREATMENT OF SPOROZOITE-INDUCED VIV AX MALARIA (CHESSON STRAIN) 1
• Kinetics of immunosuppression of sporozoite-induced immunity by Mycobacterium bovis BCG.
• COMPARISON OF CHLOROQUINE, QUINACRINE (ATABRINE), AND QUININE IN THE TREATMENT OF ACUTE ATTACKS OF SPOROZOITE-INDUCED VIV AX MALARIA (CHESSON STRAIN) 1